Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2014-12-22 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
关于收购深圳市北科生物科技有限公司13%股权的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement by 中源协和细胞基因工程股份有限公司 regarding the acquisition of a 13% equity stake in 深圳市北科生物科技有限公司. It details the transaction overview, parties involved, business and financial data of the target company, asset valuation, and terms of the acquisition agreement. The document includes financial figures and audit report references but is primarily focused on the transaction announcement rather than presenting a full financial report or audit report itself. It is not a full Annual Report, Interim Report, or Audit Report, nor is it a regulatory certification or voting result. The content fits the category of Capital/Financing Update as it announces a significant equity acquisition and related financing details. The document length (5228 characters) and detailed transaction information support this classification with high confidence.
2014-12-22 Chinese
干细胞生物工程股份公司拟收购深圳市北科生物科技有限公司股权项目涉及的深圳市北科生物科技有限公司股东全部权益价值资产评估报告
Audit Report / Information Classification · 95% confidence The document is an asset valuation report related to the acquisition of Shenzhen Beike Biotechnology Co., Ltd. by Zhongyuan Xiehe Stem Cell Bioengineering Co., Ltd. It is titled as an "资产评估报告" (Asset Evaluation Report) and contains detailed valuation methods, asset and liability assessments, and financial data as of August 31, 2014. The report is prepared by an independent asset appraisal firm and includes audit opinions. The content is focused on valuation for a capital transaction (acquisition) rather than a general annual or quarterly financial report. It is not a regulatory announcement, certification, or a brief summary but a comprehensive valuation report. This fits the category of an Audit Report / Information (AR), which includes standalone audit and valuation reports related to accounting and financial assessments outside of full annual or interim reports. Therefore, the appropriate classification is AR with high confidence. Q3 2014
2014-12-22 Chinese
深圳市北科生物科技有限公司审计报告
Audit Report / Information Classification · 95% confidence The document is titled '审计报告' which translates to 'Audit Report'. It contains detailed financial statements including consolidated balance sheets, profit and loss statements, cash flow statements, changes in shareholders' equity, and notes to the financial statements. The document also includes extensive accounting policies, accounting estimates, and explanations of accounting treatments such as business combinations, financial instruments, and foreign currency translation. The length of the document is substantial (15,000 characters), indicating it is a full report rather than a brief announcement. The content is consistent with a standalone audit report that accompanies or is part of financial reporting but is not the full annual report itself. Therefore, the document fits the category of Audit Report / Information (AR). 9M 2014
2014-12-22 Chinese
关于独立董事辞职的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of an independent director from the company's board. It details the resignation, the impact on board composition, and the company's plan to fill the vacancy. There is no financial data, no mention of financial results, no regulatory filings about audits or reports, and no mention of shareholder votes or meetings. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2014-12-22 Chinese
2014年第九次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as materials for the 2014 Ninth Extraordinary General Meeting of Shareholders of Zhongyuan Xiehe Cell Gene Engineering Co., Ltd. It includes the meeting agenda, voting procedures, and detailed descriptions of a strategic cooperation framework agreement to be voted on by shareholders. The content is focused on the meeting logistics, agenda items, and shareholder voting, rather than financial statements or earnings data. There is no indication of financial results, audit opinions, or management discussion of financial performance. The document is a meeting material for a shareholders' meeting, specifically an extraordinary general meeting, and includes agenda and voting information. Therefore, it fits the category of AGM Information (AGM-R). The document length is about 5745 characters, which is consistent with detailed meeting materials rather than a brief announcement or a full annual report.
2014-12-22 Chinese
签署关于（南方）细胞基因工程产业化基地之战略框架合作协议的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the signing of a strategic framework cooperation agreement between the company and other parties for the construction of a cell gene engineering industrialization base. It details the cooperation parties, project overview, investment scale, government support, and the impact on the company. There are no financial statements, quarterly or annual results, or audit information. The document is a formal announcement of a strategic cooperation agreement, not a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Capital Update. It is also not a management change or voting result announcement. The document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about a strategic cooperation agreement and project investment plan, which does not fit other specific categories.
2014-12-15 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.